Skip to main content

Table 2 Distribution of clinical characteristics by peripheral basophils level

From: Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer

Characteristics

 

Low basophils (n = 40)

 

High basophils (n = 23)

 

p value

Age, mean (SD)

 

52.0 (14.0)

 

54.3 (10.0)

 

0.366

Gender

Male

20

50.0%

16

69.6%

0.131

 

Female

20

50.0%

9

30.4%

 

ECOG PS

0

27

67.5%

17

73.9%

0.593

 

1 ~ 2

13

32.5%

6

26.1%

 

BMI, mean (SD)

 

21.3 (2.91)

 

21.1 (3.05)

 

0.687

Tumor location

GEJ

9

22.5%

6

26.1%

0.748

 

Stomach

31

77.5%

17

73.9%

 

Tumor differentiation

Well-moderate

4

10.0%

2

8.7%

0.968

 

Poor

32

80.0%

19

82.6%

 
 

Unknown

4

10.0%

2

8.7%

 

Lines of anti-PD-1 therapy

First line

24

60.0%

12

52.2%

0.546

 

Second line or later

16

40.0%

11

47.8%

 

Cycles of anti-PD-1 therapy, median (IQR)

 

5 (4–8)

 

5 (4–7)

 

0.549

HER2 status

Positive

5

12.5%

2

8.7%

0.644

 

Negative

35

87.5%

21

91.3%

 

PD-L1 expression

CPS ≥ 1

33

82.5%

17

73.9%

0.417

 

CPS < 1

7

17.5%

6

26.1%

 

MMR status

pMMR

36

90.0%

17

73.9%

0.042

 

dMMR

3

7.5%

1

4.3%

 
 

Unknown

1

2.5%

5

21.7%

 

EBV status

Positive

2

5.0%

2

8.7%

0.199

 

Negative

35

87.5%

16

69.6%

 
 

Unknown

3

7.5%

5

21.7%

 

Number of organs with metastasis, median (IQR)

 

2.0 (1–2)

 

2 (1–2)

 

0.637

NLR, mean (SD)

 

3.80 (3.15)

 

2.77 (1.68)

 

0.357

LMR, mean (SD)

 

2.91 (4.90)

 

3.21 (1.16)

 

0.539

  1. ECOG PS Eastern Cooperative Oncology Group Performance Status, BMI Body mass index, GEJ gastroesophageal junction, PD-1 programmed death-1, IQR interquartile range, HER2 human epidermal growth factor receptor-2, PD-L1 programmed death ligand 1, CPS combined positive score, MMR mismatch repair, pMMR proficient mismatch repair, dMMR deficient mismatch repair, EBV Epstein-Barr Virus, NLR neutrophil-to-lymphocyte ratio, LMR lymphocyte-to-monocyte ratio